Recent events
Recent events tied to this brand in public sources.
Back to profile22 entries · Page 1 of 2
2022
Altos Labs announces Hal Barron as incoming CEO and co-chair
Altos Labs announced that Hal Barron would become its CEO and co-chair; he was scheduled to step down from GSK effective August 1 to join Altos.
2021
Watsons launches more than 1,600 Sustainable Choices products
Watsons launched more than 1,600 “Sustainable Choices” products in stores and online, in collaboration with global supplier partners.
2021
Virginia woman files Zantac cancer lawsuit
Deborah Haskins sued the makers of Zantac, alleging that the drug caused her esophageal cancer and that its makers failed to warn consumers of the risks. The article says research had not explicitly linked Zantac to cancer.
2021
FDA approves Nucala for chronic rhinosinusitis with nasal polyps
The FDA approved Nucala as an add-on maintenance treatment for adults with chronic rhinosinusitis with nasal polyps who have an insufficient response to nasal corticosteroids.
2021
FDA approves Shingrix for immunocompromised adults
The US Food and Drug Administration approved Shingrix for prevention of shingles in adults aged 18 and older at increased risk due to immunodeficiency or immunosuppression caused by known disease or therapy, GlaxoSmithKline said.
2021
Evotec acquires GlaxoSmithKline’s Verona site
Evotec acquired the Verona site from GlaxoSmithKline. The site was to be named Campus Levi-Montalcini.
2021
AstraZeneca sues Glaxo over Zejula licensing agreement
AstraZeneca filed a lawsuit in the U.K. against GlaxoSmithKline, alleging that a 2012 licensing agreement over the Zejula cancer drug was breached and seeking a greater share of sales.
2020
FDA approves BENLYSTA for adult active lupus nephritis
The US Food and Drug Administration approved GSK's BENLYSTA for adults with active lupus nephritis who are receiving standard therapy, extending the US indication to include lupus nephritis for intravenous and subcutaneous formulations.
2020
GSK pledges $10 million for Philadelphia STEM equity effort
GSK pledged $10 million over the next decade to help Black, Latino, and female students in Philadelphia pursue STEM careers. The grant will be channeled through the Philadelphia STEM Equity Collective, a collaboration involving GSK and other organizations.
2020
FDA approves Blenrep for relapsed/refractory multiple myeloma
The U.S. Food and Drug Administration approved Blenrep for certain patients with relapsed or refractory multiple myeloma who have received four prior therapies. The approval was granted under accelerated approval based on the DREAMM-2 study.
2020
GSK and CureVac agree mRNA vaccine collaboration
GlaxoSmithKline and CureVac announced a strategic collaboration agreement covering the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens. CureVac's existing COVID-19 mRNA and rabies vaccine research programmes are excluded.
2020
Federal Court fines GSK and Novartis over Osteo Gel marketing
The Federal Court ordered GlaxoSmithKline to pay $1.5 million and Novartis to pay $3 million after the companies admitted breaching Australian consumer law through their marketing of Osteo Gel between 2012 and 2017. The court found that the marketing misled consumers about the product's effectiveness compared with Emulgel.
2020
GSK and Samsung Biologics agree on biopharmaceutical manufacturing capacity
GSK and Samsung Biologics announced a deal under which Samsung Biologics will provide GSK with flexible capacity for large-scale biopharmaceutical manufacturing. The agreement initially covers commercial production of Benlysta, with technology transfer starting in 2020 and first commercial supply expected in 2022.
2020
HUL board approves acquisition of Horlicks brand
HUL's board approved acquiring the Horlicks health drink brand from GSK for EUR 375.6 million (Rs 3,045 crore), exercising an option in the original agreement between Unilever and GSK. The source reports board approval, not completion of this acquisition.
2020
Bora Pharmaceuticals announces acquisition of GSK's Canadian pharmaceutical plant
Bora Pharmaceuticals announced that it would acquire a GSK subsidiary's Canadian pharmaceutical plant for NT$830 million. The article says the plant is in the Greater Toronto Area.
2020
Bora Pharmaceuticals signs five-year manufacturing contract with GSK
Bora Pharmaceuticals announced a five-year drug manufacturing contract in connection with its acquisition of GSK's Canadian plant.
2020
GlaxoSmithKline signs potential cancer immunotherapy research partnership
GlaxoSmithKline signed a potential research partnership with a German biotech to research and develop T-cell-based therapies.
2020
FDA approves Voltaren Arthritis Pain for OTC use
The U.S. Food and Drug Administration approved Voltaren Arthritis Pain as an over-the-counter product for temporary relief of arthritis pain in adults.
2019
GSK announces global Zantac recall
GlaxoSmithKline said it was recalling prescription-only Zantac medicines in all markets as a precaution after the U.S. Food and Drug Administration found unacceptable levels of a probable cancer-causing impurity in the drug. GSK said it was also suspending the release, distribution and supply of all dose forms of Zantac products.
2019
GSK announces planned INDUCE-3 trial
GlaxoSmithKline announced that it would support a planned Phase II/III trial combining GSK3359609 with pembrolizumab for first-line recurrent or metastatic head and neck squamous cell carcinoma. The trial was planned to start by the end of 2019.